APEG-PCL Nanoparticles Containing Rifampicin Target Dopaminergic Neurons to reduce α-synuclein aggregation
Objective: There were accumulating evidence proving that rifampicin could protect neurons from apoptosis in Parkinson's disease in-vitro model by regulating SUMO modification of α-synuclein. However,…Autonomic dysfunction and its correlation witn synucleinopathy: an immunohistological study in Tunisian patients with parkinson disease
Objective: Identify autonomic digestive symptoms of Parkinson disease (PD)Identify correlations between autonomic dysfunction and alpha-synuclein immunochemical staining in the upper digestive tract. Background: Pathological processes…Blood microRNA-7 as a Progression Biomarker in Parkinson’s disease
Objective: This study investigates the use of microRNA-7-5p (miR-7-5p) as a potential biomarker for Parkinson’s disease (PD) progression. Background: MiR-7-5 is a microRNA that regulates…Anti-α-synuclein antibody 5G4 differentiates idiopathic REM Sleep Behavior Disorder patients from healthy controls in skin biopsies
Objective: The aim of our study was to assess α-synuclein (α-syn) staining using the 5G4 antibody in skin samples of patients with idiopathic REM Sleep…Alpha-synuclein fibril-based mouse model of REM sleep behavior disorder as a prodrome of synucleinopathy
Objective: To investigate whether in wild-type mice, inoculation of α-synuclein (aSyn) preformed fibrils (PFFs) into the sublaterodorsal tegmental nucleus (SLD), a core structure associated with…Investigation of Modifiers of β-Glucocerebrosidase in Cell Models of Parkinson’s Disease
Objective: We firstly aim to identify modifiers of β-glucocerebrosidase (GCase) activity and expression in Parkinson’s disease (PD) relevant cell models. We secondly aim to ascertain…A novel alpha-synuclein gene (SNCA) missense variant in an Austrian familiy with atypical neuropathological features
Objective: To offer clinical, genetic and neuropathological information in a novel alpha-synuclein gene (SNCA) missense variant to further our understanding of synucleinopathies. Background: Around 5–10% of…Utilising multiple murine models to investigate sleep and circadian system dysfunction in PD
Objective: We aimed to investigate the impact of alpha-synuclein aggregation and spreading, and nigrostriatal dopaminergic degeneration on sleep homeostasis and circadian function. Background: Sleep dysfunction…Safety, Target Engagement and Effects of Bosutinib in Dementia with Lewy Bodies
Objective: To investigate the safety, biomarkers effects and determine the lowest effective dose of Bosutinibin Dementia with Lewy Bodies (DLB) Background: The effects of bosutinib,…Development of C-terminal α-Synuclein Vaccine for Treatment and Prevention of Parkinson’s Disease and Other Synucleinopathies
Objective: Prothena is developing active vaccine candidates targeting α-synuclein (α-syn) epitopes shown in clinical and/or preclinical studies to disrupt synuclein pathology. These vaccines, which target…
- « Previous Page
- 1
- …
- 33
- 34
- 35
- 36
- 37
- …
- 70
- Next Page »